TREATMENT DATA INDICATORS IN THE UNODC DATA COLLECTION SYSTEM

1. TREATMENT DATA INDICATORS IN THE UNODC DATA COLLECTION SYSTEM

2. IMPORTANCE OF TDI EXPERIENCES IN EUROPE FOR UNODC • EU WORK ON HARMONIZATION OF DATA COLLECTION SYSTEMS PROVIDES IMPORTANT GUIDANCE ON HOW TO WORK AT GLOBAL LEVEL. • TREATMENT DATA ARE IN MANY COUNTRIES THE ONLY DATA COLLECTED AND IMPROVING THEM IS AN IMPORTANT ELEMENT OF BUILDING NATIONAL INFORMATION SYSTEM.

3. REPORTING ON DRUG DEMAND REDUCTION • Developing an information set to measure achievement in respect of the targets detailed in the Political Declaration and the Demand Reduction Declaration • Goals for 2003: establishment of legal measures and programmes (reviewed during the Ministerial Segment of the Commission on Narcotic Drugs in April 2003) • Goals for 2008: to significantly reduce demand for illicit drugs.

4. ACTION PLAN ON DEMAND REDUCTION Under the Action Plan UNODC has been given 3 specific tasks: • To facilitate sharing of good practice strategies and programmes • To provide assistance in developing DDR strategies in line with the Guiding principles of drug demand reduction • To provide assistance for the establishment of national data collection systems.

5. GUIDING PRINCIPLES OF UNDCP DATA COLLECTION STRATEGY • Sensitivity to different information resources • Based on agreed standards of good practice • Comparability with other information sets

6. BIENNIAL REPORTS QUESTIONNAIRE (BRQ)on Demand Reduction Activities • Mandated follow-up instrument of the UNGASS process • To enable Member States to report on the progress achieved in meeting the UNGASS objectives for 2003 and 2008 • To monitor structures, methods of working, target population, extent and coverage of programmes, difficulties encountered

7. BIENNIAL REPORTS QUESTIONNAIRE (BRQ)on Demand Reduction Activities • Extent of coverage (low /medium or high) and programme execution (gender sensitive and evaluated in the areas of treatment and rehabilitation: • detoxification • substitution treatment (therapy) excluding short-term detoxification • non-pharmacological treatment • social reintegration

8. ANNUAL REPORTS QUESTIONNAIRE (ARQ)on Drug Abuse • To review the progress made in meeting the challenges set out in the Political Declaration adopted by the General Assembly • To monitor and increase global understanding of the extent and nature of drug abuse

9. ANNUAL REPORTS QUESTIONNAIRE (ARQ) Quantitative estimates and expert opinions on: • prevalence of drug abuse among general and youth population • prevalence of drug abuse among the school (youth) population • injecting drug abuse • severe drug abuse • new developments in prevalence and patterns of drug abuse • drug-related morbidity (HIV, HBV, HCV) • Drug-related mortality • drug treatment • data collection capacity

10. ANNUAL REPORTS QUESTIONNAIRE (ARQ) • Annually distributed to all Member States • Annual Reports Questionnaire, 2001:103 submissions, response rate 54 % • Electronic completion and submission made possible

11. ANNUAL REPORTS QUESTIONNAIRE (ARQ) TREATMENT DEMAND • Summary Expert Opinions • Have people received treatment yes/no by drugs • Ranking drugs as primary cause of receiving treatment • Trends in the past in number of people receiving treatment (large/some increase/decrease or stable)

12. ANNUAL REPORTS QUESTIONNAIRE (ARQ) TREATMENT DEMAND • Quantitative Estimates • Estimated number of people receiving treatment • Percentage of people receiving treatment for first time ever • Percentage of females • Mean age • Percentage of drug injectors • Definition of “people treated for drug problems”

17. Estimated mean age of people in treatment for cannabis type

18. Estimated percentage of females among people in treatment for cannabis type

19. Global Assessment Programme on Drug Abuse (GAP) The Global Assessment Programme (GAP) on Drug Abusehas facilitated an understanding of and improved information on the global drug situation. Lisbon consensus January 2000 agreement on a set of core Indicators • Prevalence and incidende general population • Prevalence and incidence youth population • High-risk drug abuse • Drug-related morbidity • Drug-related mortality

20. Global Assessment Programme on Drug Abuse (GAP) At the national level the GAP has: • conducted information, need and resource analyses to produce strategic action plans • Supported the establishment of data collection focal points and expert networks • Provided training and resources to meet key information needs

21. Global Assessment Programme (GAP) Through its regional activities: • GAP has supported regional information systems • Encouraged networking among countries • Provided opportunities for training At the global level: • Dissemination of methodological developments and best practices (toolkit with modules on information systems, school surveys, estimation techniques, data management and analysis) • Improved reporting standards • Increased the quality and coverage of the global information base

22. Global Assessment Programme (GAP) next steps • Technical support to regional sub-programmes and national epidemiological units • Further development and harmonization of indicators and data collection methodologies • Regional network development and exchange of information, experience and survey results among national epidemiological units in the region; • Promotion of the use of existing training packages (“methodological toolkit”) developed under the GAP and provision of technical assistance for regional training;

23. Global Assessment Programme (GAP) next steps • Development of training packages and organization of regional training programmes on: • ARQ data management and interpretation to support policy planning; • Qualitative research and focused assessment studies; • Ethical issues and principles for drug abuse epidemiology; • Treatment reporting (possible cooperation with EMCDDA and other agencies); • Monitoring of injecting drug abuse and associated HIV-related factors • Technical assistance to national focal points in collection of national and regional data on drug abuse